KRAS/P53 突变型肺腺癌中 CDK4 和 RAF1 失活后的肿瘤消退和耐药机制。
Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
机构信息
Experimental Oncology, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas, 28029 Madrid, Spain.
School of Life Sciences and Technology, Tongji University, 200092 Shanghai, China.
出版信息
Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24415-24426. doi: 10.1073/pnas.2002520117. Epub 2020 Sep 10.
Abstract
KRAS mutant lung adenocarcinomas remain intractable for targeted therapies. Genetic interrogation of KRAS downstream effectors, including the MAPK pathway and the interphase CDKs, identified CDK4 and RAF1 as the only targets whose genetic inactivation induces therapeutic responses without causing unacceptable toxicities. Concomitant CDK4 inactivation and RAF1 ablation prevented tumor progression and induced complete regression in 25% of KRAS/p53-driven advanced lung tumors, yet a significant percentage of those tumors that underwent partial regression retained a population of CDK4/RAF1-resistant cells. Characterization of these cells revealed two independent resistance mechanisms implicating hypermethylation of several tumor suppressors and increased PI3K activity. Importantly, these CDK4/RAF1-resistant cells can be pharmacologically controlled. These studies open the door to new therapeutic strategies to treat KRAS mutant lung cancer, including resistant tumors.
摘要
KRAS 突变型肺腺癌仍然对靶向治疗具有抗性。对 KRAS 下游效应物（包括 MAPK 通路和间期 CDK）的遗传研究表明，只有 CDK4 和 RAF1 是唯一的靶点，其遗传失活可诱导治疗反应而不会引起不可接受的毒性。同时抑制 CDK4 和 RAF1 可阻止肿瘤进展，并使 25%的 KRAS/p53 驱动的晚期肺肿瘤完全消退，但有相当比例的部分消退的肿瘤仍保留了一部分 CDK4/RAF1 耐药细胞。对这些细胞的特征分析揭示了两种独立的耐药机制，涉及多个肿瘤抑制因子的高甲基化和 PI3K 活性增加。重要的是，这些 CDK4/RAF1 耐药细胞可以通过药理学方法进行控制。这些研究为治疗 KRAS 突变型肺癌（包括耐药肿瘤）开辟了新的治疗策略。
相似文献
1
Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.KRAS/P53 突变型肺腺癌中 CDK4 和 RAF1 失活后的肿瘤消退和耐药机制。
Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24415-24426. doi: 10.1073/pnas.2002520117. Epub 2020 Sep 10.
2
RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression.RAF1激酶活性对于KRAS/p53突变型肺肿瘤进展并非必需。
Cancer Cell. 2021 Mar 8;39(3):294-296. doi: 10.1016/j.ccell.2021.01.008. Epub 2021 Jan 28.
3
A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.CDK4/6 抑制剂增强了携带突变型 KRAS 和野生型 KRAS 的肺腺癌细胞中紫杉醇的细胞毒性。
Cancer Biol Ther. 2013 Jul;14(7):597-605. doi: 10.4161/cbt.24592. Epub 2013 May 10.
4
Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer.靶向 CDK4 克服 KRAS 突变型肺癌中 EMT 介导的肿瘤异质性和治疗抵抗。
JCI Insight. 2021 Sep 8;6(17):e148392. doi: 10.1172/jci.insight.148392.
5
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.p65BTK 是 KRAS 突变/EGFR 野生型肺腺癌的一个新的潜在可操作靶点。
J Exp Clin Cancer Res. 2019 Jun 14;38(1):260. doi: 10.1186/s13046-019-1199-7.
6
The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.MEK 抑制剂联合靶向程序性死亡受体 1 和程序性死亡配体 1 的免疫调节抗体可延长 Kras/p53 驱动的肺癌患者的生存时间。
J Thorac Oncol. 2019 Jun;14(6):1046-1060. doi: 10.1016/j.jtho.2019.02.004. Epub 2019 Feb 13.
7
c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.c-RAF 消融通过一种不依赖于 MAPK 信号的机制诱导晚期 Kras/Trp53 突变型肺腺癌的消退。
Cancer Cell. 2018 Feb 12;33(2):217-228.e4. doi: 10.1016/j.ccell.2017.12.014. Epub 2018 Jan 27.
8
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.联合抑制 EGFR 和 C-RAF 可使晚期胰腺导管腺癌完全消退。
Cancer Cell. 2019 Apr 15;35(4):573-587.e6. doi: 10.1016/j.ccell.2019.03.002. Epub 2019 Apr 8.
9
Targeting KRAS mutant lung cancer: light at the end of the tunnel.靶向 KRAS 突变型肺癌：隧道尽头的曙光。
Mol Oncol. 2022 Mar;16(5):1057-1071. doi: 10.1002/1878-0261.13168. Epub 2022 Jan 18.
10
mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.mTOR 介导了一种对化疗产生抵抗的机制，并定义了一种合理的联合治疗策略，用于治疗 KRAS 突变型肺癌。
Oncogene. 2019 Jan;38(5):622-636. doi: 10.1038/s41388-018-0479-6. Epub 2018 Aug 31.
引用本文的文献
1
Cryo-shocked tumor cells deliver CRISPR-Cas9 for lung cancer regression by synthetic lethality.冷冻休克肿瘤细胞通过合成致死作用递送 CRISPR-Cas9 以实现肺癌消退。
Sci Adv. 2024 Mar 29;10(13):eadk8264. doi: 10.1126/sciadv.adk8264.
2
Experimental models for cancer brain metastasis.癌症脑转移的实验模型
Cancer Pathog Ther. 2023 Oct 29;2(1):15-23. doi: 10.1016/j.cpt.2023.10.005. eCollection 2024 Jan.
3
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.CRAF 在癌症进展中的作用：从分子机制到精准治疗。
Nat Rev Cancer. 2024 Feb;24(2):105-122. doi: 10.1038/s41568-023-00650-x. Epub 2024 Jan 9.
4
Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.靶向 CRAF 激酶的抗癌治疗：进展与机遇。
Mol Cancer. 2023 Dec 18;22(1):208. doi: 10.1186/s12943-023-01903-x.
5
Wild-type C-Raf gene dosage and dimerization drive prostate cancer metastasis.野生型C-Raf基因剂量和二聚化驱动前列腺癌转移。
iScience. 2023 Nov 17;26(12):108480. doi: 10.1016/j.isci.2023.108480. eCollection 2023 Dec 15.
6
Oncogenic dependency plays a dominant role in the immune response to cancer.致癌依赖性在癌症的免疫反应中起着主导作用。
Proc Natl Acad Sci U S A. 2023 Oct 10;120(41):e2308635120. doi: 10.1073/pnas.2308635120. Epub 2023 Oct 2.
7
Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022.BRAF抑制剂研发历程中的挑战与机遇：2002年至2022年
ACS Omega. 2023 Jul 26;8(31):27819-27844. doi: 10.1021/acsomega.3c00332. eCollection 2023 Aug 8.
8
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.阿贝西利在帕博西尼耐药的激素受体阳性转移性乳腺癌中有效。
Cancer Res. 2023 Oct 2;83(19):3264-3283. doi: 10.1158/0008-5472.CAN-23-0705.
9
miR-31/QKI-5 axis facilitates cell cycle progression of non-small-cell lung cancer cells by interacting and regulating p21 and CDK4/6 expressions.miR-31/QKI-5 轴通过相互作用和调节 p21 和 CDK4/6 的表达促进非小细胞肺癌细胞的细胞周期进程。
Cancer Med. 2023 Feb;12(4):4590-4604. doi: 10.1002/cam4.5309. Epub 2022 Sep 29.
10
Targeting CDK4 and CDK6 in cancer.针对癌症中的 CDK4 和 CDK6。
Nat Rev Cancer. 2022 Jun;22(6):356-372. doi: 10.1038/s41568-022-00456-3. Epub 2022 Mar 18.
本文引用的文献
1
Targeting the MAPK Pathway in KRAS-Driven Tumors.针对 KRAS 驱动肿瘤的 MAPK 通路。
Cancer Cell. 2020 Apr 13;37(4):543-550. doi: 10.1016/j.ccell.2020.03.013.
2
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.临床 KRAS(G12C) 抑制剂 AMG 510 可引发抗肿瘤免疫。
Nature. 2019 Nov;575(7781):217-223. doi: 10.1038/s41586-019-1694-1. Epub 2019 Oct 30.
3
R-spondin family members as novel biomarkers and prognostic factors in lung cancer.R-spondin家族成员作为肺癌的新型生物标志物和预后因素。
Oncol Lett. 2019 Oct;18(4):4008-4015. doi: 10.3892/ol.2019.10778. Epub 2019 Aug 22.
4
Detection of NRG1 Gene Fusions in Solid Tumors.检测实体瘤中的 NRG1 基因融合。
Clin Cancer Res. 2019 Aug 15;25(16):4966-4972. doi: 10.1158/1078-0432.CCR-19-0160. Epub 2019 Apr 15.
5
NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination.自然杀伤细胞介导的细胞毒性有助于细胞抑制剂药物组合控制肿瘤。
Science. 2018 Dec 21;362(6421):1416-1422. doi: 10.1126/science.aas9090.
6
Therapeutic strategies to target RAS-mutant cancers.靶向 RAS 突变型癌症的治疗策略。
Nat Rev Clin Oncol. 2018 Nov;15(11):709-720. doi: 10.1038/s41571-018-0105-0.
7
Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.LKB1 突变增强了曲美替尼与放疗联用对 KRAS 突变型非小细胞肺癌的放射增敏作用。
Clin Cancer Res. 2018 Nov 15;24(22):5744-5756. doi: 10.1158/1078-0432.CCR-18-1489. Epub 2018 Aug 1.
8
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.阿贝西利：一种用于治疗激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌的细胞周期蛋白依赖性激酶4/6抑制剂。
Drug Des Devel Ther. 2018 Feb 16;12:321-330. doi: 10.2147/DDDT.S137783. eCollection 2018.
9
c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.c-RAF 消融通过一种不依赖于 MAPK 信号的机制诱导晚期 Kras/Trp53 突变型肺腺癌的消退。
Cancer Cell. 2018 Feb 12;33(2):217-228.e4. doi: 10.1016/j.ccell.2017.12.014. Epub 2018 Jan 27.
10
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition.耐药物持久性癌细胞易受谷胱甘肽过氧化物酶4（GPX4）抑制的影响。
Nature. 2017 Nov 9;551(7679):247-250. doi: 10.1038/nature24297. Epub 2017 Nov 1.
Zotero 插件